Evidence map›Paper›PMID 33577808›Full record

ReviewAntiviral research2021

Emerging antiviral therapeutics for human adenovirus infection: Recent developments and novel strategies.

Mackenzie J Dodge, Katelyn M MacNeil, Tanner M Tessier, Jason B Weinberg, Joe S Mymryk

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Antiviral research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
9.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 75 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Antiviral activity ofFrontiers in pharmacology · 2025
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Mackenzie J DodgeDepartment of Microbiology and Immunology, The University of Western Ontario, London, ON, Canada.
Katelyn M MacNeilDepartment of Microbiology and Immunology, The University of Western Ontario, London, ON, Canada.
Tanner M TessierDepartment of Microbiology and Immunology, The University of Western Ontario, London, ON, Canada.
Jason B WeinbergDepartment of Pediatrics, University of Michigan, Ann Arbor, MI, USA; Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA.
Joe S MymrykDepartment of Microbiology and Immunology, The University of Western Ontario, London, ON, Canada; Department of Otolaryngology, Head & Neck Surgery, The University of Western Ontario, London, ON, Canada; Department of Oncology, The University of Western Ontario, London, ON, Canada; London Regional Cancer Program, Lawson Health Research Institute, London, ON, Canada. Electronic address: jmymryk@uwo.ca.
Western University · CAUniversity of Michigan · US

Funding

Modulation of T Cell Function by Adenovirus PersistenceR21AI142073 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WEINBERG, JASON BRICE · 2019 to 2020
$429k
CIHR MOP-148689NIAID NIH HHS R21 AI142073
6 · The paper itself

Abstract

Human adenoviruses (HAdV) are ubiquitous human pathogens that cause a significant burden of respiratory, ocular, and gastrointestinal illnesses. Although HAdV infections are generally self-limiting, pediatric and immunocompromised individuals are at particular risk for developing severe disease. Currently, no approved antiviral therapies specific to HAdV exist. Recent outbreaks underscore the need for effective antiviral agents to treat life-threatening infections. In this review we will focus on recent developments in search of potential therapeutic agents for controlling HAdV infections, with a focus on those targeting post-entry stages of the virus replicative cycle.

Indexed as

Active Transport, Cell NucleusAdenoviruses, HumanAdenovirus Infections, HumanAntiviral AgentsDNA ReplicationDrug RepositioningDrug Therapy, CombinationEpigenesis, GeneticGene ExpressionHumansImmunotherapy, AdoptiveT-LymphocytesVirus ReplicationAntiviral AgentsAdenovirusAntiviralCidofovirDrug repurposingDrug synergyHost-pathogen interactionsOutbreakSynthetic-lethal

Identifiers

PMID33577808
PMCPMC7965347
OpenAlexW3128621058

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.